You are here

  • Home
  • Archive
  • Volume 2, Issue Suppl 3
  • Converting tumors into vaccine manufacturing factories: DC recruitment, activation and clinical responses with a flt3L-primed in situ vaccine for low-grade lymphoma [nct01976585]

Article info

Article menu

Download PDFPDF

Poster Presentation
Converting tumors into vaccine manufacturing factories: DC recruitment, activation and clinical responses with a flt3L-primed in situ vaccine for low-grade lymphoma [nct01976585]
Free

Authors

Citation

Bhardwaj N, Merad M, Kim-Schulze S, et al
Converting tumors into vaccine manufacturing factories: DC recruitment, activation and clinical responses with a flt3L-primed in situ vaccine for low-grade lymphoma [nct01976585]
Journal for ImmunoTherapy of Cancer 2014;2:P45. doi: 10.1186/2051-1426-2-S3-P45

Publication history

  • First published November 6, 2014.
Online issue publication 
March 11, 2020

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© The Author(s). 2014